Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a

BusinesswireApr 23 20:31

J&J Sets Guidance Below Consensus as MedTech Underperforms

Seeking AlphaApr 16 19:20

Benchmark: Reiterates Ligand Pharmaceuticals (LGND.US) rating, adjusted from buy to buy rating, target price of $95.00.

Benchmark: Reiterates Ligand Pharmaceuticals (LGND.US) rating, adjusted from buy to buy rating, target price of $95.00.

Zhitong FinanceApr 12 21:20

Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $95 Price Target

Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $95 price target.

BenzingaApr 12 21:14

While Shareholders of Ligand Pharmaceuticals (NASDAQ:LGND) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown

While it may not be enough for some shareholders, we think it is good to see the Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) share price up 12% in a single quarter. But that doesn't help the

Simply Wall StApr 11 21:59

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Captisol-enabled Topiramate Injection shown to be a substitute for an oral dose on a one-to-one basis Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partners at the University of

BusinesswireApr 8 20:15